Recent studies have revealed that ARID1A loss impairs IFN signaling, especially Th1-type chemokine (CXCL9 and CXCL10) expression, to compromise effector T-cell tumor trafficking and antitumor immunity31. This evidence concerns the gene ARID1A and neoplasm.